Fact sheet: Woodford PatientCapTrt

Fund information

Fund name
Woodford Patient Capital Trust PLC ORD 1P
Fund company manager
Woodford Investment Management
Fund type
ITR
Fund manager
Paul Lamacraft
since 21/04/2015
Fund objective
To achieve long-term capital growth through investing in a portfolio consisting predominantly of UK companies, both quoted and unquoted. The Company will aim to deliver a return in excess of 10% per annum over the longer term.
Benchmark
-
Investment style
Growth
Investment method
Shares

Performance snapshot

Quick stats

1 Year return

-1.08 %

1 Year rank in sector

15/16

Sector

IT UK All Companies

Yield
-
Fund size

£ 765.0 m

FE Risk score

125

NAV

101.24

Discount/Premium

+-8.633

Gearing

100

Top in sector

Holdings snapshot

  • UK
    87%
  • USA
    22.21%
  • Norway
    3.54%
  • Ireland
    2.05%
  • Switzerland
    0.98%
  • Health Care
    66.46%
  • Financials
    31.04%
  • Technology
    7.5%
  • Industrials
    6.46%
  • Telecommunications
    2.7%
  • UK Equities
    87%
  • US Equities
    22.21%
  • Norwegian Equities
    3.54%
  • Irish Equities
    2.05%
  • Swiss Equities
    0.98%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund-1.18 %1.7 %-1.49 %0 %0 %
Sector-2.14 %11.53 %19.49 %22.91 %88.94 %
Rank within sector5 / 1615 / 1615 / 16 / /
Quartile th2 nd4 th4 th th th

Calendar performance

YTD-20172016201520142013
Fund1.65 %-9.75 %0 %0 %0 %
Sector10.94 %3.81 %9.09 %-1.69 %31.32 %
Rank within sector14 / 1615 / 16 / / /
Quartile th4 th4 th th th th

Price movement

52 week high98.45
52 week low81
Current bid price92.45
Current offer price92.5
Current mid price92.5

Holdings by region

  • 87% UK
  • 22.21% USA
  • 3.54% Norway
  • 2.05% Ireland
  • 0.98% Switzerland
  • 0.56% Luxembourg
  • -16.34% Money Market

Holdings by sector

  • 66.46% Health Care
  • 31.04% Financials
  • 7.5% Technology
  • 6.46% Industrials
  • 2.7% Telecommunications
  • 1.89% Consumer Goods
  • 0.29% Basic Materials
  • -16.34% Money Market

Holdings by asset type

  • 87% UK Equities
  • 22.21% US Equities
  • 3.54% Norwegian Equities
  • 2.05% Irish Equities
  • 0.98% Swiss Equities
  • 0.56% Luxembourg Equities
  • -16.34% Money Market

Individual holdings

  • 13.62% PROTHENA CORP PLC
  • 10.36% PURPLEBRICKS GROUP PLC
  • 8.66% OXFORD NANOPORE
  • 7.37% IMMUNOCORE A
  • 5.38% THERAVANCE BIOPHARMA INC
  • 4.3% MEREO BIOPHARMA GROUP LTD
  • 4.14% PROTON PARTNERS INTERNATIONAL
  • 3.31% OXFORD SCIENCES INNOVATION
  • 2.83% ATOM BANK (UNQUOTED)
  • 2.7% GIGACLEAR LTD